omalizumab(Xolair)
Anti-IgE monoclonal antibody
Pronunciation
/oʊməˈlɪzʊmæb/
International Phonetic Alphabet (IPA). Say it aloud once — you will remember it forever.
At a glance
- Generic name
- omalizumab
- Brand names
- Xolair
- Therapeutic class
- Anti-IgE monoclonal antibody
- Mechanism (summary)
- <!-- AI-DRAFTED: 2026-06-24 -->
Clinical pearls
- Administered as SC injection in clinical setting; observe for 2 hours after first dose.
- Auto-injector approved for at-home use after several in-office doses.
- Do not abruptly stop inhaled corticosteroids when starting.
- Report itching, throat tightness, swelling - signs of anaphylaxis.
- May need 12-16 weeks to see asthma benefit.
Sources
See how omalizumab appears in NAPLEX-style questions
PharmDHub Premium includes a full drug card, dosing, boxed warnings, drug-drug interactions, and practice questions built around this drug.